- Conditions
- Idiopathic Parkinson Disease
- Interventions
- Tozadenant
- Drug
- Lead sponsor
- Biotie Therapies Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 79
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Istradefylline 40 mg, Istradefylline 20 mg, Placebo
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
- Conditions
- Parkinson's Disease
- Interventions
- Rotigotine, Placebo
- Drug · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 7
- States / cities
- Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more
- Conditions
- Parkinson Disease, Idiopathic
- Interventions
- Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
- Drug · Dietary Supplement
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Parkinson's Disease (Disorder)
- Interventions
- IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
- Drug · Other
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
- Conditions
- Parkinson Disease
- Interventions
- NeuraLight
- Other
- Lead sponsor
- NeuraLight
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]), Sham Surgery
- Drug · Procedure
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 6 more
- Conditions
- Parkinson's Disease
- Interventions
- ExAblate Transcranial System
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Safinamide (as add-on therapy)
- Drug
- Lead sponsor
- Newron Pharmaceuticals SPA
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
- Conditions
- Parkinson's Disease
- Interventions
- Rotigotine
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 31 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 37
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 34 more
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- PF-06649751, Trimethobenzamide Hydrochloride, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 3 more
- Conditions
- Parkinson Disease, Idiopathic Parkinson Disease
- Interventions
- N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
- Dietary Supplement · Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lewy Body Dementia
- Interventions
- LY3154207, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
- Conditions
- Parkinson's Disease
- Interventions
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Aliso Viejo, California • Irvine, California + 17 more
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17,667 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Parkinson's Disease
- Interventions
- TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 301 participants
- Timeline
- 2002 – 2003
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Berkley, California • Fountain Valley, California + 8 more
- Conditions
- Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
- Interventions
- NEU-411, Placebo
- Drug · Other
- Lead sponsor
- Neuron23 Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 45
- States / cities
- Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
- Conditions
- Parkinson's Disease
- Interventions
- Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
- Biological
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 45 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- [21CFR640.30] Plasma from 18 - 25 year old volunteer donors, Saline
- Biological · Other
- Lead sponsor
- The Neurology Center
- Other
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Idiopathic Parkinson's Disease
- Interventions
- Rotigotine
- Drug
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
- Conditions
- Parkinson's Disease
- Interventions
- PTC-589
- Drug
- Lead sponsor
- Edison Pharmaceuticals Inc
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- Not listed
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Parkinson's Disease, Idiopathic
- Interventions
- buntanetap/posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- Lee Silverman Voice Treatment, SpeechVive, Control
- Behavioral · Device
- Lead sponsor
- University of Massachusetts, Amherst
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- West Lafayette, Indiana • Amherst, Massachusetts